Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide health problem, but no approved medical treatment exists so far. Nuclear receptors are one of the drug targets for nonalcoholic steatohepatitis (NASH). Among them, liver X receptor (LXR) has been studied in recent years in tumors, metabolic diseases and inflammatory diseases, but its physiological and pharmacological effects in the treatment of NASH are controversial. Activation of LXR has the potential to modulate cholesterol homeostasis, induce anti-inflammatory effects and increase insulin sensitivity, but liver lipid deposition and hypertriglyceridemia are also increased. Inhibition of liver LXR transcriptional activity in the context of NAFLD can effectively alleviate hepatic steatosis, inflammation, and fibrosis but elevates the risk of potential cardiovascular disease. The contradictory pharmacodynamic effects of LXR in the treatment of NASH increase the difficulty of developing targeted drugs. Moreover, natural compounds play an important part in drug development, and in recent years, some natural compounds have been reported to treat NAFLD by acting on LXR or LXR pathways with fewer adverse reactions, presenting a promising therapeutic prospect. In this review, we discuss the mechanisms of LXR in NASH and summarize the natural products reported to modulate NAFLD via LXR or the LXR pathway, offering an alternative approach for LXR-related drug development in NAFLD.

• Authors: Mingzhu Ni, Binbin Zhang, Jianan Zhao, Qin Feng, Jinghua Peng, Yiyang Hu, Yu Zhao
• Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 113 Pg. 108778 (May 2019) ISSN: 1950-6007 [Electronic] France
• PMID: 30897538 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Chemical References

• Biological Products
• Liver X Receptors
• Receptors, Cytoplasmic and Nuclear
• Cholesterol

Topics

• Animals
• Biological Products (pharmacology)
• Cholesterol (metabolism)
• Drug Development (methods)
• Humans
• Insulin Resistance
• Liver X Receptors (metabolism)
• Molecular Targeted Therapy
• Non-alcoholic Fatty Liver Disease (drug therapy, physiopathology)
• Receptors, Cytoplasmic and Nuclear (metabolism)